Engene reports full year 2023 financial results and recent operational progress

Achieved primary and secondary endpoints in phase 1 portion of legend study in non-muscle invasive bladder cancer (nimbc); pivotal portion underway with interim data expected mid this year completed a reverse merger transaction with forbion european acquisition corp (feac), launched as a public company on november 1, 2023, and completed an upsized pipe financing combined transactions resulted in net proceeds of approximately $109 million closed an expanded $50m debt facility with hercules capital in december 2023; extends cash runway into q2 2025 boston and montreal , jan. 29, 2024 /prnewswire/ - engene holdings inc. (nasdaq: engn) (or "engene" or the "company"), a clinical-stage genetic medicines company whose non-viral lead program is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced its financial results for the fiscal year ended october 31, 2023 and provided a corporate update. "during 2023, engene made substantial progress advancing our lead program, eg-70 (detalimogene voraplasmid), in our ongoing pivotal-stage legend study in bcg-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
ENGN Ratings Summary
ENGN Quant Ranking